Hundreds of breast cancer patients in England are currently unable to access a life-extending drug, trastuzumab deruxtecan, also known as Enhertu, due to an ongoing dispute over its price. The medication, which has shown significant promise in clinical trials, is designed for individuals with HER2-low metastatic breast cancer, a form of the disease where the cancer has spread to other parts of the body and is considered incurable.
The National Institute for Health and Care Excellence (NICE) has not yet recommended Enhertu for routine use within the NHS in England. This decision stems from a failure to agree on a cost that NICE deems an appropriate use of NHS resources, despite the drug's demonstrated benefits. For many patients, Enhertu could offer precious additional months of life, with an average extension of six months reported in studies, and some individuals experiencing even longer periods of stable disease.
The situation in England contrasts with other parts of the UK. Patients in Scotland can access Enhertu through the New Medicines Fund, an interim funding mechanism designed to bridge the gap between regulatory approval and full NICE appraisal. Similarly, patients in Wales are able to receive the drug through specific funding pathways. This disparity means that access to a potentially life-prolonging treatment is dependent on a patient's postcode within the UK.
Cancer charities and patient advocacy groups have voiced significant concerns over the delay, highlighting the emotional toll on patients and their families. They argue that every month counts for individuals with advanced cancer, and that bureaucratic hurdles should not stand in the way of accessing effective treatments. The manufacturer, AstraZeneca, has expressed a commitment to working with NICE to reach a resolution, but a timeline for agreement remains unclear.
This ongoing dispute underscores broader challenges within the NHS regarding the adoption of new, often expensive, innovative cancer therapies. Balancing the need to provide cutting-edge treatments with the financial sustainability of the health service is a constant tension. While negotiations continue, eligible patients in England are left without a treatment option available to their counterparts elsewhere in the UK.
Patients concerned about their treatment options should consult their GP or oncology team. For general health advice, NHS 111 is available.
Source: BBC